Can Higher Doses of Oxybutynin Improve Efficacy in Neurogenic Bladder?
Authors:
- 1 February 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 171 (2) , 749-751
Abstract
We evaluated the efficacy and tolerability of higher dose oxybutynin chloride in patients with neurogenic bladder and multiple sclerosis, spinal cord injury or Parkinson's disease. The study design was a prospective, 12-week dose titration trial of controlled release oxybutynin (OXY-XL). A 7-day washout period was used before initiation of the starting dose of 10 mg OXY-XL. Doses of OXY-XL were increased by 5 mg at weekly intervals to a maximum dose of 30 mg per day guided by patient perception of efficacy versus side effect. Voiding diaries were completed at baseline, and weeks 6 and 12. Post-void residuals were recorded. Criteria for study admission included post-void residual less than 200 ml. Of the 39 patients enrolled in the study 22 had multiple sclerosis, 10 had spinal cord injury and 7 had Parkinson's disease. There were 29 women (74%) and 10 men (26%). Within 1 week a decrease in the number of voids per day was seen in greater than 50% of the subjects. At the end of the study statistically significant decreases in the number of voids in 24 hours, episodes of nocturia and incontinence episodes were observed. Residual urine remained unchanged from 33.9 +/- 7.6 ml at baseline to 51.3 +/- 10.4 ml after 12 weeks at the final dose (p = 0.17). No patient experienced serious adverse events and none dropped out during the course of the 12-week study. At the end of the study 20.5% of subjects remained on 30 mg, 15.4% on 25 mg, 23.1% on 20 mg, 15.4% on 15 mg and 25.6% on 10 mg OXY-XL. Aggressive dosing of OXY-XL is safe and effective in patients with neurogenic bladder. Compared with nonneurogenic overactive bladder, higher doses of OXY-XL (15 mg daily or greater) were requested by 74.4% of the patients in our study. The onset of clinical efficacy can occur within 1 week, and doses up to 30 mg are well tolerated and effective in this population.Keywords
This publication has 18 references indexed in Scilit:
- Dry mouth with conventional and controlled-release oxybutynin in urinary incontinenceObstetrics & Gynecology, 2000
- Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinenceUrology, 1999
- ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCEJournal of Urology, 1999
- An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladderClinical Therapeutics, 1999
- Contemporary urologic management of patients with spinal cord injury.Mayo Clinic Proceedings, 1998
- HIGH INCIDENCE OF OCCULT NEUROGENIC BLADDER DYSFUNCTION IN NEUROLOGICALLY INTACT PATIENTS WITH THORACOLUMBAR SPINAL INJURIESJournal of Urology, 1998
- URODYNAMICS OF SPINAL CORD INJURYUrologic Clinics of North America, 1996
- Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- Sleep Disturbance, Depression, and Lesion Site in Patients With Multiple SclerosisArchives of Neurology, 1992
- Conservative therapy of frequency, urgency and urge incontinence: A double-blind clinical trial of flavoxate hydrochloride, exybutinin chloride, emepronium bromide and placeboWorld Journal of Urology, 1987